These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32337492)

  • 1. Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    Mai PL; Miller A; Gail MH; Skates S; Lu K; Sherman ME; Ioffe OB; Rodriguez G; Cohn DE; Boggess J; Rutherford T; Kauff ND; Rader JS; Phillips KA; DiSilvestro PA; Olawaiye AB; Ridgway MR; Greene MH; Piedmonte M; Walker JL
    JNCI Cancer Spectr; 2020 Feb; 4(1):pkz075. PubMed ID: 32337492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a
    Stuursma A; van der Vegt B; Jansen L; Berger LPV; Mourits MJE; de Bock GH
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
    Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
    J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L
    Gynecol Oncol; 2017 Apr; 145(1):122-129. PubMed ID: 28190649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Mai PL; Huang HQ; Wenzel LB; Han PK; Moser RP; Rodriguez GC; Boggess J; Rutherford TJ; Cohn DE; Kauff ND; Phillips KA; Wilkinson K; Wenham RM; Hamilton C; Powell MA; Walker JL; Greene MH; Hensley ML
    Gynecol Oncol; 2020 Jan; 156(1):131-139. PubMed ID: 31759774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
    van Driel CM; de Bock GH; Arts HJ; Sie AS; Hollema H; Oosterwijk JC; Mourits MJ
    Maturitas; 2015 Mar; 80(3):318-22. PubMed ID: 25600260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
    Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
    Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
    Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
    Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.